These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 28843746)

  • 1. Cytological and histological changes in the urothelium produced by electromotive drug administration (EMDA) and by the combination of intravescical hyperthermia and chemotherapy (thermochemotherapy).
    Pierconti F; Straccia P; Emilio S; Bassi PF; De Pascalis I; Marques RC; Volavsek M; Larocca LM; Lopez-Beltran A
    Pathol Res Pract; 2017 Sep; 213(9):1078-1081. PubMed ID: 28843746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The risk of malignancy of atypical urothelial cells of undetermined significance in patients treated with chemohyperthermia or electromotive drug administration.
    Pierconti F; Rossi ED; Straccia P; Fadda G; Larocca LM; Bassi PF; Sacco E; Schinzari G
    Cancer Cytopathol; 2018 Mar; 126(3):200-206. PubMed ID: 29360198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravesical electromotive drug administration for non-muscle invasive bladder cancer.
    Jung JH; Gudeloglu A; Kiziloz H; Kuntz GM; Miller A; Konety BR; Dahm P
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011864. PubMed ID: 28898400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Electromotive Drug Administration of Mitomycin C (EMDA/MMC) versus Intravesical Immunotherapy with Bacillus Calmette-Guérin (BCG) in Intermediate and High Risk Non Muscle Invasive Bladder Cancer.
    Zazzara M; Nazaraj A; Scarcia M; Cardo G; Carando R; Ludovico GM
    Urol Int; 2023; 107(1):64-71. PubMed ID: 34933307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
    Di Stasi SM; Valenti M; Verri C; Liberati E; Giurioli A; Leprini G; Masedu F; Ricci AR; Micali F; Vespasiani G
    Lancet Oncol; 2011 Sep; 12(9):871-9. PubMed ID: 21831711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk "BCG failure" non muscle invasive bladder cancer: 3 years follow-up outcomes.
    Racioppi M; Di Gianfrancesco L; Ragonese M; Palermo G; Sacco E; Bassi PF
    BMC Cancer; 2018 Dec; 18(1):1224. PubMed ID: 30522445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review of the efficacy of intravesical electromotive drug administration therapy for non-muscle invasive bladder cancer.
    Melgarejo-Segura MT; Morales-Martínez A; Yáñez-Castillo Y; Arrabal-Polo MÁ; Gómez-Lechuga P; Pareja-Vílchez M; Jiménez-Moleón JJ; Martín MA
    Urol Oncol; 2023 Apr; 41(4):166-176. PubMed ID: 36328923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Updates in intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer.
    Di Stasi SM; Riedl C
    World J Urol; 2009 Jun; 27(3):325-30. PubMed ID: 19234707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary cytokines in patients treated with intravesical mitomycin-C with and without hyperthermia.
    Arends TJ; Falke J; Lammers RJ; Somford DM; Hendriks JC; de Weijert MC; Arentsen HC; van der Heijden AG; Oosterwijk E; Alfred Witjes J
    World J Urol; 2015 Oct; 33(10):1411-7. PubMed ID: 25491674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder.
    Halachmi S; Moskovitz B; Maffezzini M; Conti G; Verweij F; Kedar D; Sandri SD; Nativ O; Colombo R
    Urol Oncol; 2011; 29(3):259-64. PubMed ID: 19395285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential administration of Bacillus Calmette-Guerin (BCG) and Electromotive Drug Administration (EMDA) of mitomycin C (MMC) for the treatment of high-grade nonmuscle invasive bladder cancer after BCG failure.
    Juvet T; Mari A; Lajkosz K; Wallis CJ; Kuk C; Erlich A; Krimus L; Fleshner NE; Kulkarni GS; Zlotta AR
    Urol Oncol; 2020 Nov; 38(11):850.e9-850.e15. PubMed ID: 32712139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Intravesical therapy with mitomycin through electromotive drug administration].
    Verri C; Liberati E; Celestino F; De Carlo F; Torelli F; Di Stasi SM
    Urologia; 2013; 80(2):105-11. PubMed ID: 23852927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of device-assisted therapies in the management of non-muscle invasive bladder cancer: A systematic review.
    Carando R; Pradere B; Afferi L; Marra G; Aziz A; Roghmann F; Krajewski W; Di Bona C; Alvarez-Maestro M; Pagliarulo V; Xylinas E; Moschini M
    Prog Urol; 2020 May; 30(6):322-331. PubMed ID: 32279953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma.
    Paroni R; Salonia A; Lev A; Da Pozzo LF; Cighetti G; Montorsi F; Rigatti P; Colombo R
    Br J Clin Pharmacol; 2001 Sep; 52(3):273-8. PubMed ID: 11560559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single ablative intravesical electromotive mitomycin C administration for small non-muscle-invasive bladder cancer: a prospective study.
    Decaestecker K; Lumen N; Van Camp C; Oosterlinck W
    Acta Clin Belg; 2018 Oct; 73(5):324-327. PubMed ID: 29451102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential Treatment With Bacillus Calmette-Güerin (BCG) and Mitomycin C Administered With Electromotive Drug Administration (EMDA) in Patients With High-Risk Nonmuscle Invasive Bladder Cancer After BCG Failure.
    Sanz Gómez I; Huguet J; Bravo A; Robalino J; Rodríguez Faba Ó; Territo Á; Gaya JM; Palou J; Breda A
    Clin Genitourin Cancer; 2023 Aug; 21(4):e286-e290. PubMed ID: 37076337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectivity of intravescical thermo-chemotherapy prophylaxis for patients with high recurrence and progression risk for non-muscle invasive bladder cancer.
    Gözen AS; Umari P; Scheitlin W; Su FE; Akin Y; Rassweiler J
    Arch Ital Urol Androl; 2017 Jun; 89(2):102-105. PubMed ID: 28679178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of a new device for intravesical thermochemotherapy in non-grade 3 BCG recurrent NMIBC: a phase I-II study.
    Soria F; Milla P; Fiorito C; Pisano F; Sogni F; Di Marco M; Pagliarulo V; Dosio F; Gontero P
    World J Urol; 2016 Feb; 34(2):189-95. PubMed ID: 26026818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Intravesical instillations in non-muscle-invasive bladder cancer (NMIBC). Prospects for thermochemotherapy].
    Irani J
    Prog Urol; 2016 Nov; 26(14):860-864. PubMed ID: 27712914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of hyperthermia as a treatment for non-muscle invasive bladder cancer.
    Bahouth Z; Halachmi S; Moskovitz B; Nativ O
    Expert Rev Anticancer Ther; 2016; 16(2):189-98. PubMed ID: 26618756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.